Get the Stockscreener App
4.12
1.44%
-0.06
Pre-market:
4.12
Sab Biotherapeutics Inc stock is traded at $4.12, with a volume of 307.31K.
It is down -1.44% in the last 24 hours and up +10.16% over the past month.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
See More
Previous Close:
$4.18
Open:
$4.17
24h Volume:
307.31K
Relative Volume:
0.93
Market Cap:
$196.14M
Revenue:
$114.70K
Net Income/Loss:
$-37.06M
P/E Ratio:
-1.0318
EPS:
-3.9929
Net Cash Flow:
$-30.69M
1W Performance:
+3.52%
1M Performance:
+10.16%
6M Performance:
+90.74%
1Y Performance:
+140.94%
1-Day Range:
$4.06
$4.265
1-Week Range:
$3.75
$4.30
52-Week Range:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Name
Sab Biotherapeutics Inc
Sector
Industry
Phone
305-845-2813
Address
777 W 41ST ST, MIAMI BEACH
Compare SABS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
4.12 | 199.00M | 114.70K | -37.06M | -30.69M | -3.9929 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | Guggenheim | Buy |
| Sep-17-25 | Initiated | Leerink Partners | Outperform |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Oct-09-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Nov-05-21 | Initiated | Chardan Capital Markets | Buy |
View All
Sab Biotherapeutics Inc Stock (SABS) Latest News
SAB BIO to Participate in Upcoming Investor Conferences - Investing News Network
Aug Momentum: Whats the profit margin of SAB Biotherapeutics Inc Equity WarrantTrade Entry Summary & Risk Controlled Daily Plans - baoquankhu1.vn
SAB Biotherapeutics, Inc. Management to Participate in February Investor Conferences - Quiver Quantitative
Biotech firm SAB Biotherapeutics joins fireside chats at 2 Feb. investor events - Stock Titan
Published on: 2026-01-31 17:26:58 - baoquankhu1.vn
Can SAB Biotherapeutics Inc. weather a recessionJuly 2025 Price Swings & Long-Term Safe Return Strategies - mfd.ru
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in SAB Biothe - GuruFocus
SAB Biotherapeutics Shares Jump 33% After Securing $175M in Oversubscribed Private Placement - MSN
Aug Patterns: Whats HTGCs historical return2025 Investor Takeaways & Low Risk Growth Stock Ideas - baoquankhu1.vn
Insider Sell: Is SAB Biotherapeutics Inc a cyclical or defensive stockQuarterly Trade Summary & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Investment Review: Whats the profit margin of SAB Biotherapeutics Inc Equity WarrantQuarterly Risk Review & High Conviction Investment Ideas - baoquankhu1.vn
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Aug Mood: Is SAB Biotherapeutics Inc Equity Warrant stock undervalued right nowJuly 2025 Earnings & Low Drawdown Trading Techniques - baoquankhu1.vn
SAB Biotherapeutics phase 1 trial of SAB-142 met primary endpoint - MSN
HB Wealth Management LLC Buys New Stake in SAB Biotherapeutics, Inc. $SABS - MarketBeat
Portfolio Update: Will SAB Biotherapeutics Inc. Equity Warrant stock continue upward momentumTrend Reversal & Growth Focused Entry Point Reports - Bộ Nội Vụ
Published on: 2026-01-13 04:34:13 - Улправда
SAB Biotherapeutics, Inc. Updates on SAB-142 Development - TradingView
SAB Biotherapeutics (NASDAQ:SABS) Earns Buy Rating from Analysts at UBS Group - Defense World
UBS Group Upgrades SAB Biotherapeutics (NASDAQ:SABS) to "Strong-Buy" - MarketBeat
Cash per share of SAB Biotherapeutics, Inc. Warrant 2021-22.10.26 on SAB Biotherap – NASDAQ:SABSW - TradingView — Track All Markets
Will SAB Biotherapeutics Inc. stock continue dividend increasesJuly 2025 Levels & Daily Profit Focused Stock Screening - Улправда
Why SAB Biotherapeutics Inc. stock remains on buy listsJuly 2025 Movers & Verified Momentum Stock Watchlist - Улправда
Will SAB Biotherapeutics Inc. stock see insider buying2025 Earnings Impact & Risk Adjusted Buy and Sell Alerts - Улправда
Is SAB Biotherapeutics Inc. stock a buy on dipsMarket Growth Summary & High Accuracy Swing Entry Alerts - ulpravda.ru
Why SAB Biotherapeutics Inc. stock attracts global investorsQuarterly Market Review & Detailed Earnings Play Strategies - Улправда
Why SAB Biotherapeutics Inc. Equity Warrant stock is recommended by analystsJuly 2025 Volume & High Win Rate Trade Tips - Улправда
Los Angeles Daily NewsSAB Biotherapeutics, Inc.Common Stock (Nasdaq:SABS) Stock Quote - FinancialContent
Published on: 2026-01-07 16:05:26 - bollywoodhelpline.com
UBS Initiates Coverage of SAB Biotherapeutics (SABS) with Buy Recommendation - Nasdaq
SAB Biotherapeutics, Inc.Warrant (NQ: SABSW - FinancialContent
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director - GlobeNewswire
Two veteran drug leaders join the board behind a new Type 1 diabetes therapy - Stock Titan
SAB Biotherapeutics stock initiated with Buy rating at UBS on diabetes drug potential - Investing.com Canada
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Significant Increase in Short Interest - MarketBeat
SAB Biotherapeutics Launches New $75 Million ATM Program - The Globe and Mail
SAB Biotherapeutics Files $300 Million Mixed Shelf - MarketScreener
Sab Biotherapeutics files for offering of up to $300 mln - marketscreener.com
SAB Biotherapeutics enters sales agreement with UBS SecuritiesSEC filing - MarketScreener
SAB Biotherapeutics Enters Sales Agreement With UBS SecuritiesSEC Filing - TradingView — Track All Markets
SAB Biotherapeutics Establishes New At-the-Market Offering Program - TradingView — Track All Markets
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is SAB Biotherapeutics Inc. stock a good choice for value investorsBlue Chip Stock Analysis & Free Professional Investment Consultations - bollywoodhelpline.com
SABS SEC FilingsSAB BIOTHERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
SAB Biotherapeutics Earnings Notes - Trefis
Will SAB Biotherapeutics Inc. Equity Warrant stock continue dividend increases2025 Pullback Review & AI Forecasted Entry and Exit Points - Улправда
What margin trends mean for SAB Biotherapeutics Inc. stockJuly 2025 Setups & Verified Entry Point Detection - Улправда
Guggenheim Initiates Coverage of SAB Biotherapeutics (SABS) with Buy Recommendation - Nasdaq
Guggenheim Initiates Coverage on SAB Biotherapeutics With Buy Rating, $15 Price Target - marketscreener.com
Guggenheim initiates SAB Biotherapeutics stock with Buy rating on T1D potential - Investing.com Canada
Sab Biotherapeutics Inc Stock (SABS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sab Biotherapeutics Inc Stock (SABS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sessa Capital (Master), L.P. | Director |
Sep 29 '25 |
Option Exercise |
1.75 |
1,740,000 |
3,045,000 |
2,198,457 |
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):